title: Helicobacter pylori infection in Chile.
abstract: This article summarizes studies designed to evaluate the role of Helicobacter pylori infection in Chile, described in 21 reports from nine centers in various Chilean regions published between 1985 and 1995. According to their data, H. pylori infection is quite frequent among patients with a variety of gastric conditions, including adults (43%-92%) and children (6%-100%). Levels of specific IgG antibodies to H. pylori are also elevated among patients with duodenal ulcers (100%) and gastritis (86%) as well as asymptomatic adults (75%). Combination therapy with three (but not two) drugs has been proved effective, with clinical improvement, ulcer cure, and H. pylori eradication occurring in well-controlled studies. Available evidence suggests that antibiotic resistance is not a major problem in treatment. The H. pylori reinfection rate is low (4.2% per year), suggesting that combination therapy with three drugs constitutes a cost-effective alternative for treating colonized symptomatic patients. Concurrent preliminary studies revealed that antibodies to VacA but not CagA proteins correlate with disease severity in Chilean patients. It can be concluded that local research assists local administrators of health resources to implement adequate policies to prevent, control, and treat H. pylori-related pathologies.
authors.affiliation: Institute of Nutrition and Food Technology and Faculty of Medicine, University of Chile, Santiago.
authors.forename: G
authors.initials: G
authors.lastname: Figueroa
authors.forename: R
authors.initials: R
authors.lastname: Acuña
authors.forename: M
authors.initials: M
authors.lastname: Troncoso
authors.forename: D P
authors.initials: DP
authors.lastname: Portell
authors.forename: M S
authors.initials: MS
authors.lastname: Toledo
authors.forename: J
authors.initials: J
authors.lastname: Valenzuela
mesh_terms: D002677:Chile / Q000453:epidemiology; D005544:Forecasting; D016481:Helicobacter Infections / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D016480:Helicobacter pylori / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans